Want to see SE:XBRANE full AI Analyst Report?
Top Page
Xbrane Biopharma AB
(XBRANE)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr9.50
▼(-8.39% Downside)
Action:Reiterated
Date:07/20/26
The score is held back primarily by weak financial performance driven by ongoing operating losses and significant negative operating/free cash flow, despite a currently supportive balance sheet. Technicals are broadly neutral without strong trend confirmation. Valuation looks low on P/E, but the signal is tempered by the company’s weak profitability and cash burn.
Positive Factors
Biosimilar business model
Biosimilars address healthcare-cost pressures by offering alternatives to expensive biologics. Xbrane’s development, manufacturing-strategy and partnering capabilities provide a platform for recurring commercialization and licensing opportunities.
Negative Factors
Persistent cash burn
Materially negative operating and free cash flow means the business does not currently fund its activities internally. Continued development spending and commercialization requirements may require financing or balance-sheet support, creating dilution and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Biosimilar business model
Biosimilars address healthcare-cost pressures by offering alternatives to expensive biologics. Xbrane’s development, manufacturing-strategy and partnering capabilities provide a platform for recurring commercialization and licensing opportunities.
Read all positive factors
Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr201.11M
Dividend YieldN/A
Average Volume (3M)22.08K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth-68.66%
EPS Growth-137.27%
CountrySE
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding20,605,349
10 Day Avg. Volume20,390
30 Day Avg. Volume22,080
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-39.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.94
Revenue Forecast (FY)kr185.40M
Xbrane Biopharma AB Business Overview & Revenue Model
Company Description
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ran...
How the Company Makes Money
Xbrane makes money primarily through biosimilar-related commercialization and partnering economics. Key revenue streams can include: (1) Net sales/royalties and related commercial income from biosimilar products where Xbrane has a commercial inter...
Xbrane Biopharma AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.30M | 152.35M | 198.70M | 238.73M | 57.62M | 11.53M |
| Gross Profit | -5.12M | 74.94M | 180.47M | 35.39M | 41.04M | -684.00K |
| EBITDA | -60.62M | -16.50M | -181.97M | -282.03M | -149.34M | -167.59M |
| Net Income | -75.00M | 127.24M | -266.22M | -388.17M | -172.23M | -191.01M |
Balance Sheet | ||||||
| Total Assets | 642.61M | 671.62M | 842.43M | 653.51M | 690.51M | 688.43M |
| Cash, Cash Equivalents and Short-Term Investments | 49.50M | 86.59M | 124.33M | 65.40M | 193.99M | 295.18M |
| Total Debt | 63.71M | 58.31M | 191.72M | 231.48M | 38.22M | 44.38M |
| Total Liabilities | 103.76M | 110.97M | 633.89M | 482.17M | 265.63M | 256.69M |
| Stockholders Equity | 538.85M | 560.65M | 208.54M | 171.34M | 424.89M | 431.74M |
Cash Flow | ||||||
| Free Cash Flow | -141.35M | -390.33M | -185.97M | -423.45M | -254.04M | -296.96M |
| Operating Cash Flow | -130.31M | -250.69M | -133.73M | -406.68M | -193.92M | -219.61M |
| Investing Cash Flow | -85.17M | -37.14M | -52.25M | -16.77M | -60.13M | -77.35M |
| Financing Cash Flow | 263.19M | 255.60M | 243.62M | 298.70M | 148.86M | 349.37M |
Xbrane Biopharma AB Technical Analysis
Neutral
10.37
Price Trends
10.11
Negative
10.24
Negative
9.61
Positive
Market Momentum
-0.10
Negative
49.34
Neutral
74.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Neutral. The current price of 10.37 is above the 20-day moving average (MA) of 9.64, above the 50-day MA of 10.11, and above the 200-day MA of 9.61, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 49.34 is Neutral, neither overbought nor oversold. The STOCH value of 74.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:XBRANE.
Xbrane Biopharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr497.63M | 2.60 | 63.09% | ― | ― | ― | |
56 Neutral | kr4.71B | -5.89 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr201.11M | -4.07 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr192.20M | -8.14 | -56.09% | ― | ― | 14.10% | |
43 Neutral | kr1.60B | -3.22 | -99.58% | ― | -87.22% | -70.29% | |
40 Underperform | kr172.73M | -0.02 | -736.08% | ― | -98.81% | 80.33% |
* Healthcare Sector Average
SE:XBRANE
Xbrane Biopharma AB
9.76
-23.84
-70.95%
SE:HNSA
Hansa Biopharma AB
46.26
15.48
50.29%
SE:ATORX
Alligator Bioscience AB
0.03
-0.91
-97.32%
SE:BINV
BioInvent International AB
24.30
-5.10
-17.35%
SE:ELIC
Elicera Therapeutics AB
2.88
-3.78
-56.78%
SE:CANTA
Cantargia AB
1.77
-0.83
-31.85%
Xbrane Biopharma AB Corporate Events
Xbrane bolsters biosimilar pipeline as Ximluci drives revenue and FDA review advances
Jul 17, 2026
Xbrane Biopharma reported second-quarter 2026 revenue of SEK 46.8 million, mainly from higher Ximluci product sales, alongside a negative EBITDA and a loss for the period. Despite the loss, cash and cash equivalents rose to SEK 49.5 million, and t...
Xbrane and JOINN Forge Partnership to Advance Darzalex Biosimilar Xdarzane
Jun 11, 2026
Xbrane Biopharma AB has entered a strategic partnership with JOINN Biologics US Inc. to advance Xdarzane, its biosimilar candidate to multiple myeloma drug Darzalex. JOINN will handle customized process development, including pilot-scale work to d...
Xbrane Wins FDA Review Date for U.S. Lucentis Biosimilar Lucamzi
Jun 3, 2026
Xbrane Biopharma AB has had its resubmitted Biologics License Application accepted by the U.S. Food and Drug Administration for Lucamzi, its investigational biosimilar candidate to Lucentis (ranibizumab), with a Biosimilar User Fee Act action date...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.